ValiRx (LSE:VAL) FCF Yield %: -79.68 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is ValiRx FCF Yield %?

ValiRx LSE:VAL FCF Yield % is -79.68 as of Jul. 15, 2026. The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, ValiRx ranks worse than 88.36% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, ValiRx's Trailing 12-Month Free Cash Flow is £-1.53 Mil, and Market Cap is £1.91 Mil. Therefore, ValiRx's FCF Yield % for today is -79.68%.

The historical rank and industry rank for ValiRx's FCF Yield % or its related term are showing as below:

LSE:VAL' s FCF Yield % Range Over the Past 10 Years
Min: -817811.57   Med: -6497.68   Max: -79.68
Current: -79.68

During the past 13 years, the highest FCF Yield % of ValiRx was -79.68%. The lowest was -817811.57%. And the median was -6497.68%.

LSE:VAL's FCF Yield % is ranked worse than
88.36% of 1409 companies
in the Biotechnology industry
Industry Median: -9.54 vs LSE:VAL: -79.68

ValiRx's FCF Margin % for the quarter that ended in Dec. 2025 was -1,677.42%.

ValiRx FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

ValiRx FCF Yield % Related Terms

ValiRx FCF Yield % Historical Data

* Premium members only.

The historical data trend for ValiRx's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ValiRx FCF Yield % Chart

ValiRx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.35 -13.56 -34.42 -55.94 -61.25

ValiRx Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.23 -45.19 -46.95 -71.83 -41.80

LSE:VAL vs VRTX, REGN, ALNY: FCF Yield % Comparison

For the Biotechnology subindustry, ValiRx's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ValiRx FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's FCF Yield % distribution charts can be found below:

* The bar in red indicates where ValiRx's FCF Yield % falls into.


ValiRx FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

ValiRx's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-1.524 / 2.48811535
=-61.25%

ValiRx's annualized FCF Yield % for the quarter that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-0.52 * 2 / 2.48811535
=-41.80%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -79.68 mean?
ValiRx (LSE:VAL) has a FCF Yield % of -79.68 as of Jul. 15, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on ValiRx and its competitors. According to the industry distribution chart, ValiRx ranks #1245 out of 1409 companies in the Biotechnology industry, placing it in the top 88.4%.
Is ValiRx's FCF Yield % too high?
ValiRx's current FCF Yield % is -79.68. Based on the distribution chart, ValiRx ranks #1245 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does ValiRx's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ValiRx ranks #1245 out of 1409 companies for FCF Yield %. This places ValiRx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on ValiRx and its competitors. ValiRx's current FCF Yield % is -79.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ValiRx stock overvalued right now?
ValiRx (LSE:VAL) has a current FCF Yield % of -79.68. The current FCF Yield % is -79.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For ValiRx (LSE:VAL), the current FCF Yield % is -79.68 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ValiRx Business Description

Other Exchanges EAJF:Germany
Address D6 Thane Road, MediCity Nottingham, Nottingham, GBR, NG90 6BH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.